Topical cyclosporine 0.05% for the prevention of dry eye disease progression

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 2, 2010, Pages 157-163

  Rao, Sanjay N ^a  

^a Lakeside Eye Group SC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL TEAR; CYCLOSPORIN A; REFRESH ENDURA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DRY EYE; EYE DISCOMFORT; FEMALE; FUNCTION TEST; GOBLET CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR SURFACE DISEASE INDEX SCORE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; SCORING SYSTEM; TEAR BREAKUP TIME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADULT; CELL COUNT; CYCLOSPORINE; DISEASE PROGRESSION; DRY EYE SYNDROMES; FEMALE; FOLLOW-UP STUDIES; GOBLET CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 77951696235     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0091     Document Type: Article

References (32)

1. Ishida, R., Koj ima, T., Dogru, M., et al. The application of a new continuous functional visual acuity measurement system in dry eye syndromes. Am. J. Ophthalmol. 139: 253-258, 2005. (Pubitemid 40288269)
2. Mertzanis, P., Abetz, L., Raj agopalan, K., et al. The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. Invest. Ophthalmol. Vis. Sci. 46: 46-50, 2005 (Pubitemid 40041177)
3. Milj anovic, B., Dana, R., Sullivan, D. A., et al. Impact of dry eye syndrome on vision-related quality of life. Am. J. Ophthalmol. 143: 409-415, 2007. (Pubitemid 46273354)
4. Lin, P. Y., Tsai, S. Y., Cheng, C. Y., et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 110: 1096-1101, 2003. (Pubitemid 36676639)
5. McCarty, C. A., Bansal, A. K., Livingston, P. M., et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 105: 1114-1119, 1998. (Pubitemid 28268339)
6. Schaumberg, D. A., Sullivan, D. A., Buring, J. E., et al. Prevalence of dry eye syndrome among US women. Am. J. Ophthalmol. 136: 318-326, 2003. (Pubitemid 36904081)
7. Milj anovic, B. M. et al. Association for research in vision and ophthalmology. Invest. Ophthalmol. Vis. Sci. 48: E-abstract 4293, 2007.
8. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007) Ocul. Surf. 5: 108-152, 2007. (Pubitemid 351902653)
9. Behrens, A., Doyle, J. J., Stern, L., et al.; Dysfunctional tear syndrome study group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 25: 900-907, 2006
10. Pfl ugfelder, S. C. Antiinfl ammatory therapy for dry eye. Am. J. Ophthalmol. 137: 337-342, 2004. (Pubitemid 38221009)
11. Stern, M. E., Beuerman, R. W., Fox, R. I., et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 17: 584-589, 1998.
12. Wilson, S. E. Infl ammation: a unifying theory for the origin of dry eye syndrome. Manag. Care. 12: 14-19, 2003.
13. Wilson, S. E., and Stulting, R. D. Agreement of physician treatment practices with the international task force guidelines for diagnosis and treatment of dry eye disease. Cornea. 26: 284-289, 2007. Restasis® [package insert]. Irvine, CA: Allergan, Inc.; 2004.
14. Matsuda, S., and Koyasu, S. Mechanisms of action of cyclosporine. Immunopharmacology. 47: 119-125, 2000. (Pubitemid 30394535)
15. Donnenfeld, E., and Pfl ugfelder, S. C. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv. Ophthalmol. 54: 321-338, 2009.
16. Kunert, K. S., Tisdale, A. S., Stern, M. E., et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch. Ophthalmol. 118: 1489-1496, 2000.
17. Turner, K., Pfl ugfelder, S. C., Ji, Z., et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 19: 492-496, 2000. (Pubitemid 30460887)
18. Bron, A J., Evans, V. E., and Smith, J. A. Grading of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests. Cornea. 22: 640-650, 2003.
19. Schiffman, R. M., Christianson, M. D., Jacobsen, G., et al. Reliability and validity of the Ocular Surface Disease Index. Arch. Ophthalmol. 118: 615-621, 2000 (Pubitemid 30327337)
20. Pfl ugfelder, S. C., De Paiva, C. S., Villarreal, A. L., et al. Effects of sequential artifi cial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 27: 64-69, 2008.
21. The defi nition and classifi cation of dry eye disease: report of the Defi nition and Classifi cation Subcommittee of the International Dry Eye WorkShop (2007) Ocul. Surf. 5: 75-92, 2007. (Pubitemid 351902651)
22. The Gallup Organization, Inc. The 2008 Gallup Study of Dry Eye Sufferers. Princeton, NJ: Multi-Sponsor Surveys, Inc.; 2008.
23. Sall, K., Stevenson, O. D., Mundorf, T. K., et al. Two multicenter, randomized studies of the effi cacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 107: 631-639, 2000. (Pubitemid 30191329)
24. Stevenson, D., Tauber, J., and Reis, B. L. Effi cacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 107: 967-974, 2000.
25. Perry, H. D., Solomon, R., Donnenfeld, E. D., et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch. Ophthalmol. 126: 1046-1050, 2008.
26. Kunert, K. S., Tisdale, A. S., and Gipson, I. K. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch. Ophthalmol. 120: 330-337, 2002.
27. Wilson, S. E., and Perry, H. D. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 114: 76-79, 2007.
28. Marsh, P., and Pflugfelder, S. C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 106: 811-816, 1999 (Pubitemid 30194327)
29. Pflugfelder, S. C., Maskin, S. L., Anderson, B., et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am. J. Ophthalmol. 138: 444-457, 2004. Lotemax [package insert]. Tampa FL: Bausch & Lomb Inc.; 2006 Lotemax [package insert]. Tampa, FL: Bausch & Lomb, Inc.; 2006. (Pubitemid 39208573)
30. Barber, L. D., Pfl ugfelder, S. C., Tauber, J., et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 112: 1790-1794, 2005. (Pubitemid 41400017)
31. Baudouin, C. The pathology of dry eye. Surv. Ophthalmol. 45 (Suppl 2): S211-S220, 2001 (Pubitemid 33052380)
32. Lemp, M. A. Evaluation and differential diagnosis of keratoconjunctivitis sicca. J. Rheumatol. Suppl. 61: 11-14, 2000.